2025 marks a turning point for the pharmaceutical industry: for the first time, drugs discovered with AI assistance are entering advanced clinical trials. This is no longer the future — it's the present of life sciences.
The first tangible successes
Several AI-identified molecules have entered Phase II and Phase III. Insilico Medicine, Exscientia, and Recursion Pharmaceuticals are demonstrating that the AI-first approach to drug discovery is not just faster but produces candidates with competitive safety and efficacy profiles. Average time from target discovery to clinical entry has decreased from 5 to 2 years.
Foundation models for life sciences
The emergence of specialized biology foundation models — like AlphaFold for protein structure prediction and ESM for protein sequences — is creating a new paradigm. These models, pre-trained on enormous biological datasets, can be fine-tuned for specific tasks with relatively limited data, democratizing AI access in life sciences.
Digital twins for clinical trials
Patient digital twins — computational models simulating individual treatment response — are becoming standard tools in clinical trial design, reducing required control arm patients and improving result predictiveness.
Regulatory challenges and opportunities
The European AI Act and new FDA and EMA guidelines are defining the regulatory framework for AI use in pharma. Companies investing today in compliance and AI process documentation will have a significant competitive advantage.